TY - JOUR
T1 - Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry
AU - Xu, Yan
AU - Keith, Bruce
AU - Grem, Jean L.
N1 - Funding Information:
Dr. Yan Xu’s one-year sabbatical at the National Cancer Institute was funded through an Interagency Personnel Agreement between the National Cancer Institute and Cleveland State University.
PY - 2004/4/5
Y1 - 2004/4/5
N2 - A liquid chromatography/mass spectrometry (LC-MS) method has been developed and validated for the determination of the anticancer agent gemcitabine (dFdC) and its metabolite 2′,2′-difluoro-2′- deoxyuridine (dFdU) in human plasma. An Oasis® HLB solid phase extraction cartridge was used for plasma sample preparation. Separation of the analytes was achieved with a YMC ODS-AQ (5μm, 120Å, 2.0mm×150mm) column. The initial composition of the mobile phase was 2% methanol/98% 5mM ammonium acetate at pH 6.8 (v/v), and the flow rate was 0.2ml/min. An isocratic gradient was used for 3min, followed by a linear gradient over 4min to 30% methanol/70% 5mM ammonium acetate at pH 6.8. The gradient returned to the initial conditions over 2min and remained there for 6min. The retention times of dFdC, dFdU, and the internal standard 5′-deoxy-5-fluorouridine (5′-DFUR) were 11.46, 12.63, and 13.58min. The mass spectrometer was operated under negative electrospray ionization conditions. Single-ion- monitoring (SIM) mode was used for analyte quantitation at m/z 262 for [dFdC-H]-, m/z 263 for [dFdU-H]-, and m/z 245 for [5′-DFUR-H]-. The average recoveries for dFdC, dFdU, and 5′-DFUR were 88.4, 84.6, and 99.3%, respectively. The linear calibration ranges were 5-1000ng/ml for dFdC, and 5-5000ng/ml for dFdU. The intra- and inter-assay precisions (%CV) were ≤3 and ≤7% at three concentration levels (50.0, 500, and 5000ng/ml). The limits of quantitation (defined as 10 times of signal-to-noise ratio) were 3.16ng/ml for dFdC, and 1.35ng/ml for dFdU with 50-μl sample injections. This method has been used for measuring plasma concentrations of dFdC and dFdU in samples from adult cancer patients in a Phase I trial of weekly dFdC given as 150 (or lower) mg/(m2 24-h) infusion. The average plasma dFdC concentrations at 22- and 23-h into the infusion were 18.3 and 16.8ng/ml at 150 and 100mg/m2, respectively; the values for dFdU averaged 2950 and 1372ng/ml.
AB - A liquid chromatography/mass spectrometry (LC-MS) method has been developed and validated for the determination of the anticancer agent gemcitabine (dFdC) and its metabolite 2′,2′-difluoro-2′- deoxyuridine (dFdU) in human plasma. An Oasis® HLB solid phase extraction cartridge was used for plasma sample preparation. Separation of the analytes was achieved with a YMC ODS-AQ (5μm, 120Å, 2.0mm×150mm) column. The initial composition of the mobile phase was 2% methanol/98% 5mM ammonium acetate at pH 6.8 (v/v), and the flow rate was 0.2ml/min. An isocratic gradient was used for 3min, followed by a linear gradient over 4min to 30% methanol/70% 5mM ammonium acetate at pH 6.8. The gradient returned to the initial conditions over 2min and remained there for 6min. The retention times of dFdC, dFdU, and the internal standard 5′-deoxy-5-fluorouridine (5′-DFUR) were 11.46, 12.63, and 13.58min. The mass spectrometer was operated under negative electrospray ionization conditions. Single-ion- monitoring (SIM) mode was used for analyte quantitation at m/z 262 for [dFdC-H]-, m/z 263 for [dFdU-H]-, and m/z 245 for [5′-DFUR-H]-. The average recoveries for dFdC, dFdU, and 5′-DFUR were 88.4, 84.6, and 99.3%, respectively. The linear calibration ranges were 5-1000ng/ml for dFdC, and 5-5000ng/ml for dFdU. The intra- and inter-assay precisions (%CV) were ≤3 and ≤7% at three concentration levels (50.0, 500, and 5000ng/ml). The limits of quantitation (defined as 10 times of signal-to-noise ratio) were 3.16ng/ml for dFdC, and 1.35ng/ml for dFdU with 50-μl sample injections. This method has been used for measuring plasma concentrations of dFdC and dFdU in samples from adult cancer patients in a Phase I trial of weekly dFdC given as 150 (or lower) mg/(m2 24-h) infusion. The average plasma dFdC concentrations at 22- and 23-h into the infusion were 18.3 and 16.8ng/ml at 150 and 100mg/m2, respectively; the values for dFdU averaged 2950 and 1372ng/ml.
KW - 2′,2′-Difluoro-2′-deoxyuridine
KW - Gemcitabine
UR - http://www.scopus.com/inward/record.url?scp=1342285674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1342285674&partnerID=8YFLogxK
U2 - 10.1016/j.jchromb.2003.11.038
DO - 10.1016/j.jchromb.2003.11.038
M3 - Article
C2 - 15018786
AN - SCOPUS:1342285674
SN - 1570-0232
VL - 802
SP - 263
EP - 270
JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
IS - 2
ER -